MicroRNA-101 Polymorphisms and Risk of Head and Neck Squamous Cell Carcinoma in a Chinese Population

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Oct 23

PMID 26490987

Citations 4

Authors

Limin Miao

Lihua Wang

Hua Yuan

Dong Hang

Longbiao Zhu

Jiangbo Du

Xun Zhu

Bing Li

Ruixia Wang

Hongxia Ma

Ning Chen

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) play important roles in regulation of gene expressions and likely have involvement in cancer susceptibility and disease progression. MicroRNA-101 (miR-101) has been well established as a tumor suppressor, and aberrant expression of miR-101 levels has been previously reported in different malignancies including head and neck squamous cell carcinoma (HNSCC). However, the role of single nucleotide polymorphisms (SNPs) of miR-101 in the susceptibility to HNSCC remains unclear. In this study, we genotyped 11 selected SNPs of the miR-101 genes (including miR-101-1 and miR-101-2) in a case-control study including 576 HNSCC cases and 1552 cancer-free controls. For the main effect analysis, none of the 11 selected SNPs was associated with HNSCC risk. However, in the stratification analysis by tumor sites, rs578481 and rs705509 in pri-miR-101-1 were significantly associated with risk of oral squamous cell carcinoma (OSCC) (rs578481: adjusted odds ratio (OR) = 1.19, 95 % confidence interval (CI) 1.01-1.39, P = 0.036; rs705509: adjusted OR = 0.85, 95 % CI 0.73-0.98, P = 0.030). Furthermore, combined analysis of the two SNPs revealed that subjects carrying the risk alleles of rs578481 and rs705509 had increased risk of OSCC in a dose-response manner (P trend = 0.022). Compared with subjects carrying "0-2" risk alleles, subjects carrying "3-4" risk alleles presented a 1.38-fold increased risk of OSCC. In conclusion, our findings suggested that the SNPs rs578481 and rs705509 locating in pri-miR-101-1 may play a role in genetic susceptibility to OSCC, which may improve our understanding of the potential contribution of miRNA SNPs to cancer pathogenesis.

Citing Articles

The Role of Single Nucleotide Polymorphisms in MicroRNA Genes in Head and Neck Squamous Cell Carcinomas: Susceptibility and Prognosis.

Szmida E, Butkiewicz D, Karpinski P, Rutkowski T, Oczko-Wojciechowska M, Sasiadek M Genes (Basel). 2024; 15(9).

PMID: 39336817 PMC: 11431317. DOI: 10.3390/genes15091226.

Effects of microRNAs polymorphism in cancer progression.

SiamiGorji S, Jorjani I, Tahamtan A, Moradi A Med J Islam Repub Iran. 2020; 34:3.

PMID: 32284927 PMC: 7139258. DOI: 10.34171/mjiri.34.3.

miRNA-101 Targets TGF-βR1 to Retard the Progression of Oral Squamous Cell Carcinoma.

Wang Y, Jia R, Diao S, He J, Jia L Oncol Res. 2019; 28(2):203-212.

PMID: 31831099 PMC: 7851522. DOI: 10.3727/096504019X15761480623959.

MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1.

Wu B, Lei D, Wang L, Yang X, Jia S, Yang Z Am J Cancer Res. 2016; 6(6):1396-407.

PMID: 27429852 PMC: 4937741.

References

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

Banerjee R, Mani R, Russo N, Scanlon C, Tsodikov A, Jing X . The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene. 2011; 30(42):4339-49. PMC: 3154567. DOI: 10.1038/onc.2011.141. View

Xiong X, Cho M, Cai X, Cheng J, Jing X, Cen J . A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. Mutat Res. 2014; 761:15-20. DOI: 10.1016/j.mrfmmm.2014.01.001. View

Semaan A, Qazi A, Seward S, Chamala S, Bryant C, Kumar S . MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹). Pharm Res. 2011; 28(12):3079-90. DOI: 10.1007/s11095-011-0547-x. View

Lei Y, Li B, Tong S, Qi L, Hu X, Cui Y . miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells. PLoS One. 2015; 10(2):e0117809. PMC: 4320037. DOI: 10.1371/journal.pone.0117809. View

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

Hu Z, Lin Y, Chen H, Mao Y, Wu J, Zhu Y . MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun. 2013; 435(1):82-7. DOI: 10.1016/j.bbrc.2013.04.042. View

Wu C, Li M, Hu C, Duan H . Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy. Cancer Chemother Pharmacol. 2013; 73(2):335-41. DOI: 10.1007/s00280-013-2364-x. View

10.

Marcu L, Yeoh E . A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment. J Cancer Res Clin Oncol. 2009; 135(10):1303-14. DOI: 10.1007/s00432-009-0648-7. View

11.

Chen J, Qin Z, Jiang Y, Wang Y, He Y, Dai J . Genetic variations in the flanking regions of miR-101-2 are associated with increased risk of breast cancer. PLoS One. 2014; 9(1):e86319. PMC: 3901682. DOI: 10.1371/journal.pone.0086319. View

12.

Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu C . MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett. 2012; 586(24):4362-70. DOI: 10.1016/j.febslet.2012.10.053. View

13.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

14.

Bae J, Kim J, Pasaje C, Cheong H, Lee T, Koh I . Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Dig Liver Dis. 2012; 44(10):849-54. DOI: 10.1016/j.dld.2012.04.021. View

15.

Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S . Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1999; 18(6B):4779-86. View

16.

da Silva S, Ferlito A, Takes R, Brakenhoff R, Valentin M, Woolgar J . Advances and applications of oral cancer basic research. Oral Oncol. 2011; 47(9):783-91. DOI: 10.1016/j.oraloncology.2011.07.004. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

18.

Orsos Z, Szanyi I, Csejtei A, Gerlinger I, Ember I, Kiss I . Association of pre-miR-146a rs2910164 polymorphism with the risk of head and neck cancer. Anticancer Res. 2012; 33(1):341-6. View

19.

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

20.

Buechner J, Tomte E, Haug B, Henriksen J, Lokke C, Flaegstad T . Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011; 105(2):296-303. PMC: 3142803. DOI: 10.1038/bjc.2011.220. View